Ethicon, a Johnson & Johnson MedTech company, today announced the approval of ETHIZIA, an adjunctive hemostat solution which can help to achieve sustained hemostasis in difficult to control bleeding situations. Comprised of unique synthetic polymer technology, ETHIZIA Hemostatic Sealing Patch is a hemostatic matrix designed to be equally active and efficacious on both sides. Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored, making it easy to handle in both open and minimally invasive surgeries. In 80% of clinical trial patients studied, ETHIZIA Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch.
ETHIZIA Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostat for disruptive bleeding on internal organs, except cardiovascular and neurological, and is expected to launch in EMEA in Q1 2024, and other key markets in North America, APAC and LATAM following regulatory approvals.
In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges. The acquisition of GATT and the addition of its synthetic technology complements Ethicon's current capabilities, enabling the development of innovative solutions that address critical unmet needs, such as ETHIZIA Hemostatic Sealing Patch which can offer sustained hemostasis in difficult to control bleeding situations.
As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized. The introduction of ETHIZIA provides a unique design that surgeons can trust to work equally effective on both sides, giving surgeons the confidence they need in any surgical situation.
